Literature DB >> 20940211

Finding studies on reboxetine: a tale of hide and seek.

Beate Wieseler1, Natalie McGauran, Thomas Kaiser.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940211     DOI: 10.1136/bmj.c4942

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  10 in total

1.  Unhealthy marketing of pharmaceutical products: An international public health concern.

Authors:  Shai Mulinari
Journal:  J Public Health Policy       Date:  2016-02-25       Impact factor: 2.222

2.  [Quality of reporting in studies on bipolar disorders: implications for the development of guidelines].

Authors:  B Soltmann; A Pfennig; B Weikert; M Bauer; D Strech
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

Review 3.  Educational Paper: Aspects of clinical pharmacology in children--pharmacovigilance and safety.

Authors:  Imti Choonara
Journal:  Eur J Pediatr       Date:  2012-10-31       Impact factor: 3.183

4.  Safety of new medicines in young children.

Authors:  Imti Choonara
Journal:  Arch Dis Child       Date:  2011-09       Impact factor: 3.791

5.  Why we need easy access to all data from all clinical trials and how to accomplish it.

Authors:  Peter C Gøtzsche
Journal:  Trials       Date:  2011-11-23       Impact factor: 2.279

6.  Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data.

Authors:  Beate Wieseler; Natalia Wolfram; Natalie McGauran; Michaela F Kerekes; Volker Vervölgyi; Petra Kohlepp; Marloes Kamphuis; Ulrich Grouven
Journal:  PLoS Med       Date:  2013-10-08       Impact factor: 11.069

Review 7.  The concept of justifiable healthcare and how big data can help us to achieve it.

Authors:  Wim van Biesen; Catherine Van Der Straeten; Sigrid Sterckx; Johan Steen; Lisa Diependaele; Johan Decruyenaere
Journal:  BMC Med Inform Decis Mak       Date:  2021-03-06       Impact factor: 2.796

8.  Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data.

Authors:  Daniel Strech; Jasper Littmann
Journal:  Trials       Date:  2012-07-02       Impact factor: 2.279

9.  A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population.

Authors:  Mattias Neyt; Hans Van Brabandt; Stephan Devriese; Stefaan Van De Sande
Journal:  BMJ Open       Date:  2012-05-04       Impact factor: 2.692

10.  Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward.

Authors:  Dimitra Panteli; Alexandra Nolting; Helene Eckhardt; Michael Kulig; Reinhard Busse
Journal:  Health Res Policy Syst       Date:  2016-01-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.